Funding
Series A · Biotech

Alchemab raises £60m Series A to develop protective-antibody therapies

RA Capital Management leads funding for the biotech company’s antibody discovery platform.

By RoundOS Funding desk

Alchemab Therapeutics announced a £60 million Series A on 15 April 2021, led by RA Capital Management. Lightstone Ventures, DCVC, DHVC, SV Health Investors and the Dementia Discovery Fund also participated.

The company studies people whose immune systems appear to protect them from disease, using antibody sequencing and computational analysis to identify potential treatments. The financing supports its discovery platform and preclinical programmes in neurodegeneration and cancer.

Use of funds

Advance protective-antibody discovery platform and preclinical neurodegeneration and cancer programmes

Funding history

Series A · This round£60M
Biomedical Catalyst grantUndisclosed

Sources

  1. Alchemab raises GBP60m Series Aalchemab.com · Apr 15, 2021

Similar rounds

All Biotech rounds →
Sunlit Seedlings

Sunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.

UndisclosedCorporate investment · Nov 13, 2026
Biomatter

Biomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.

$18MSeries A · Nov 12, 2026
Orakl Oncology

Combines patient-derived tumour organoids, clinical data and AI to help pharmaceutical companies develop cancer treatments.

$34MSeries A · Nov 12, 2026
LABTECHS

LABTECHS develops rapid sterility testing kits and reagents from research at the University of Toyama.

UndisclosedT-CAF investment commitment · Nov 11, 2026

Related